Kuderer NM - Search Results

1

Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.

Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A; American Society of Clinical Oncology. Lyman GH, et al. Among authors: kuderer nm. J Clin Oncol. 2015 Feb 20;33(6):654-6. doi: 10.1200/JCO.2014.59.7351. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605844 Free PMC article.

2

Basic population and cancer genetics and their use in the assessment of cancer risk.

Lyman GH, Kuderer NM. Lyman GH, et al. Among authors: kuderer nm. Eur J Cancer. 1997 Nov;33(13):2160-6. doi: 10.1016/s0959-8049(97)00307-9. Eur J Cancer. 1997. PMID: 9470801 Review. No abstract available.

3

Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia.

Lyman GH, Kuderer NM, Balducci L. Lyman GH, et al. Among authors: kuderer nm. Curr Opin Oncol. 1998 Jul;10(4):291-6. doi: 10.1097/00001622-199807000-00003. Curr Opin Oncol. 1998. PMID: 9702395 Review.

4

The economics of febrile neutropenia: implications for the use of colony-stimulating factors.

Lyman GH, Kuderer N, Greene J, Balducci L. Lyman GH, et al. Eur J Cancer. 1998 Nov;34(12):1857-64. doi: 10.1016/s0959-8049(98)00222-6. Eur J Cancer. 1998. PMID: 10023306

5

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.

Lyman GH, Kuderer NM, Djulbegovic B. Lyman GH, et al. Among authors: kuderer nm. Am J Med. 2002 Apr 1;112(5):406-11. doi: 10.1016/s0002-9343(02)01036-7. Am J Med. 2002. PMID: 11904116

6

Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients.

Lyman GH, Kuderer NM, Balducci L. Lyman GH, et al. Among authors: kuderer nm. Curr Opin Hematol. 2002 May;9(3):207-14. doi: 10.1097/00062752-200205000-00006. Curr Opin Hematol. 2002. PMID: 11953666 Review.

7

Filgrastim in patients with neutropenia: potential effects on quality of life.

Lyman GH, Kuderer NM. Lyman GH, et al. Among authors: kuderer nm. Drugs. 2002;62 Suppl 1:65-78. doi: 10.2165/00003495-200262001-00005. Drugs. 2002. PMID: 12479595 Review.

8

Cost effectiveness of myeloid growth factors in cancer chemotherapy.

Lyman GH, Kuderer NM. Lyman GH, et al. Among authors: kuderer nm. Curr Hematol Rep. 2003 Nov;2(6):471-9. Curr Hematol Rep. 2003. PMID: 14561391 Review.

9

Evidence-based use of colony-stimulating factors in elderly cancer patients.

Lyman GH, Kuderer N, Agboola O, Balducci L. Lyman GH, et al. Cancer Control. 2003 Nov-Dec;10(6):487-99. doi: 10.1177/107327480301000607. Cancer Control. 2003. PMID: 14652525 Free article. Review.

10

The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.

Lyman GH, Kuderer NM. Lyman GH, et al. Among authors: kuderer nm. Crit Rev Oncol Hematol. 2004 May;50(2):129-46. doi: 10.1016/j.critrevonc.2004.01.001. Crit Rev Oncol Hematol. 2004. PMID: 15157662 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

136 results

Search Page